First presentation of data from the Phase 3 randomized trial shows statistically significant and clinically meaningful improvement in progression-free surv...
Thermo Fisher Scientific, the world leader in the service of science, has received Good Manufacturing Practice (GMP) approval from the Italian Medicines Ag...
AbZelect™ and AbZelectPRO™ platforms enable the rapid generation and selection of high-yielding mammalian CHO cell lines for therapeutic protei...
New investment from DRW Venture Capital LLC and Tolmar International Ltd Funds will be used to advance its proprietary, silica-based, drug delivery...
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patien...
SyntheticGestalt, a research and development company specializing in the application of AI to the life sciences domain, and Enamine, the world's leading pr...
Approval by the Medicines and Healthcare products Regulatory Agency (MHRA) of AGAMREE® in the United Kingdom follows marketing authorization for this...
“We are very excited that our partner is moving forward with licensing the XeriJect technology to further the development of the XeriJect subcutaneou...
— NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 — — NDA is supported b...
-- VantAI’s advanced geometric deep learning platform will be used to generate innovative proximity modulating therapeutics, including molecular glue...
Pfizer Inc. announced that the European Commission (EC) has approved TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in c...
Base4 Biotechnology (formerly known as Nymirum) announced that it has expanded its license agreement with Servier to strengthen the companies' strategic co...
BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditional "hard-to-drug" targets, announced a strategic collabora...
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercial...
© 2025 Biopharma Boardroom. All Rights Reserved.
